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Introduction: Adrenomedullin (AM) is secreted by breast cancer cells and increased by hypoxia. It is a multifunctional
peptide that stimulates angiogenesis and proliferation. The peptide is also a potent paracrine stimulator of osteoblasts
and bone formation, suggesting a role in skeletal metastases—a major site of treatment-refractory tumor growth in
patients with advanced disease.
Methods: The role of adrenomedullin in bone metastases was tested by stable overexpression in MDA-MB-231
breast cancer cells, which cause osteolytic bone metastases in a standard animal model. Cells with fivefold increased
expression of AM were characterized in vitro, inoculated into immunodeficient mice and compared for their ability to
form bone metastases versus control subclones. Bone destruction was monitored by X-ray, and tumor burden and
osteoclast numbers were determined by quantitative histomorphometry. The effects of AM overexpression on tumor
growth and angiogenesis in the mammary fat pad were determined. The effects of AM peptide on osteoclast-like
multinucleated cell formation were tested in vitro. A small-molecule AM antagonist was tested for its effects on
AM-stimulated ex vivo bone cell cultures and co-cultures with tumor cells, where responses of tumor and bone
were distinguished by species-specific real-time PCR.
Results: Overexpression of AM mRNA did not alter cell proliferation in vitro, expression of tumor-secreted factors
or cell cycle progression. AM-overexpressing cells caused osteolytic bone metastases to develop more rapidly,
which was accompanied by decreased survival. In the mammary fat pad, tumors grew more rapidly with unchanged
blood vessel formation. Tumor growth in the bone was also more rapid, and osteoclasts were increased. AM peptide
potently stimulated bone cultures ex vivo; responses that were blocked by small-molecule adrenomedullin antagonists
in the absence of cellular toxicity. Antagonist treatment dramatically suppressed tumor growth in bone and decreased
markers of osteoclast activity.
Conclusions: The results identify AM as a target for therapeutic intervention against bone metastases. Adrenomedullin
potentiates osteolytic responses in bone to metastatic breast cancer cells. Small-molecule antagonists can effectively
block bone-mediated responses to tumor-secreted adrenomedullin, and such agents warrant development for testing
in vivo.Introduction
Adrenomedullin (AM) is a member of the calcitonin/
amylin/calcitonin gene-related peptide (CGRP) family dis-
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peptide, PAMP [1]. Transcription of the gene is increased
by the hypoxia-stabilized hypoxia-inducible factor 1α path-
way [2]. AM is secreted into the circulation, where it binds
to complement factor H [3]. The peptide signals via the
calcitonin receptor-like receptor plus receptor activity–
modifying protein (RAMP) 2 or 3, activating adenylate
cyclase [4]. Responses to AM include vasodilation, bron-
chodilation, angiogenesis, lymphangiogenesis, inhibition of
microbial growth, and regulation of renal function, hor-
mone secretion, cell proliferation and apoptosis [5].his is an Open Access article distributed under the terms of the Creative
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colon, ovary and breast, express AM [6,7] and its receptor
[8]. Increased AM production by tumors and high concen-
trations of the peptide in plasma correlate with lymph node
metastases in breast cancer patients, suggesting that AM
contributes to an aggressive metastatic phenotype [9]. AM
regulates cell proliferation, inhibits apoptosis and stimulates
angiogenesis in cancer cells [6,7,10]. AM inhibition de-
creases subcutaneous tumor growth of glioblastoma, lung,
colon, breast and pancreatic cancers in mice [11-14].
AM is also a potent stimulator of bone cells [15], which
express both ligand and receptor [16]. Exogenous AM pep-
tide potently stimulates new bone formation and osteoblast
proliferation through a cAMP-dependent pathway [17,18].
No effect of AM on bone-resorbing osteoclasts has been
found [19], and a role for the peptide in bone metastases
has not previously been tested.
More than 80% of breast cancers are positive for AM
expression [9], whereas other tumor types that cause
bone metastases [20] also express the peptide, which can
act on both tumor and bone cells [21]. At least 80% of
patients with advanced breast cancer have bone metasta-
ses, and survival from the time of first diagnosis of
skeletal involvement is approximately 24 months [22,23].
Bone metastases are incurable, and more effective treat-
ments are needed [20,23]. Because of its specific effects on
bone and expression by the majority of tumors, we hy-
pothesized that AM would be an enhancing rather than
primary causal factor in metastases to bone, suggesting
that AM could be a therapeutic target for treatment of
bone metastases. Stable AM expression by MDA-MB-231
human breast cancer cells was experimentally increased
fivefold to mimic the effect of hypoxia to induce AM
[2]. The cells showed unchanged molecular parameters
in vitro but increased bone metastases and mammary
fat pad (MFP) growth in vivo. Small-molecule receptor
antagonists effectively blocked the paracrine actions of
AM on bone. In a novel ex vivo model of tumor growth in
bone metastases, adding AM increased the growth of
tumor in bone and stimulated expression of the osteoclast
marker tartrate-resistant acid phosphatase (TRAP) only in
the presence of tumor while changing the cell source of
the osteoclast regulator, receptor activator of nuclear
factor κB ligand (RANKL). The AM antagonist 16311
blocked the increases in RANKL and TRAP and decreased
tumor growth in bone. The results suggest that small-
molecule antagonists may be effective against breast cancer
skeletal metastases by blocking the actions of AM to
potentiate osteolytic responses of bone to tumor.
Methods
Plasmids
The complete 1,494-nucleotide human preproAM mRNA
sequence [GenBank:BC015961] was released from thepOTB7 vector by EcoRI-PspOMI restriction enzyme
digestion and ligated between the EcoRI and NotI sites
of pIRESneo3 (Clontech Laboratories, Mountain View,
CA, USA) to create pIRESneo3-hAM. In the vector,
the cytomegalovirus (CMV) promoter drives transcrip-
tion of a bicistronic mRNA encoding both preproAM
and the neomycin resistance cassette, separated by an
internal ribosome entry site (IRES), to facilitate anti-
biotic selection of AM-expressing clones. Restriction
mapping with EcoRI and AciI confirmed the correct
orientation of the AM insert relative to the CMV pro-
moter. An emerald green fluorescent protein (emGFP)
cassette from pLenti6.2 (Invitrogen, Carlsbad, CA, USA)
was cloned into the EcoRV site of pIRESneo3 to create
pIRESneo3-emGFP for use as the vector control.
Adrenomedullin antagonists
Small-molecule antagonists of AM [24] were provided
by Dr. Frank Cuttitta of the National Cancer Institute
(NCI), National Institutes of Health (Bethesda, MD,
USA). They were dissolved in dimethyl sulfoxide, diluted
in phosphate-buffered saline (PBS), sterile-filtered and
added to bone organ cultures at the indicated final
concentrations. NSC 16311 is 2-(1-ethyl-4-hydroxy-4-
piperidyl)-2-phenyl acetic acid (CAS 5449-34-3); NSC
37133 is 2-[(4-carboxyphenyl)methyl]benzoic acid (CAS
6268-08-2); and NSC 28086 is 2-hydroxy-2,2-bis(4-
phenylphenyl)-acetic acid (CAS 6334-91-4).
Cell culture
MDA-MB-231 cells were purchased from the American
Type Culture Collection (Manassas, VA, USA) and have
been previously characterized for their behavior in a
model of bone metastasis [25]. MDA-MB-231 cells were
cultured in Dulbecco’s modified Eagle’s medium (DMEM;
Mediatech, Manassas, VA, USA) supplemented with 10%
fetal bovine serum (FBS; Atlanta Biologicals, Norcross,
GA, USA) and 1% penicillin/streptomycin. The stable
pools and single-cell clones were grown in DMEM and
10% FBS plus G418 (1,100 μg/ml and 150 μg/ml, re-
spectively). Cells were incubated at 37°C and 5% CO2
in a humidified incubator.
Isolation of stable clones
An aggressive bone metastatic variant of the human breast
cancer line MDA-MB-231 [25] was transfected with either
pIRESneo3-hAM or pIRESneo3-emGFP control using
FuGENE HD transfection reagent (Promega, Madison,
WI, USA). Cells were selected with G418 to create a
stable pool. Clones were isolated by limiting dilution in
the presence of antibiotics. Increased AM mRNA was
assayed by real-time PCR. Green fluorescent protein
(GFP) expression in control transfectants was confirmed by
fluorescence microscopy. Clones were cultured for 60 days
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GFP expression to assure phenotypic stability. Two stable
GFP and two AM-overexpressing clones with similar char-
acteristics in vitro were chosen for use in vivo to exclude
response due to clonal variability.
Detection of secreted human peptides
MDA-MB-231 parental cells—two GFP- and two AM-
overexpressing clones—were plated at 106 cells per
145-mm dish and grown to >90% confluence. Cells were
rinsed with 1× PBS and then grown in 10 ml of 0.1% bo-
vine serum albumin and 1% penicillin/streptomycin in
DMEM for 24 hours. Media were collected, mixed with
protease inhibitors (aprotinin, phenylmethylsulfonyl fluor-
ide and leupeptin), centrifuged to remove debris and
assayed for human AM and PAMP peptides with enzyme
immunoassay kits (Phoenix Pharmaceuticals, Burlingame,
CA, USA).
Determination of growth in vitro
Cells were plated at 2,500 cells per well in a 96-well plate on
day 0. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assays were performed on days 1, 3 and 5
per the manufacturer’s instructions (Promega). Optical dens-
ity was read at 570 nm (Synergy HT plate reader with KC4
v3.1 software; BioTek, Winooski, VT, USA). All values were
normalized to the value at day 1 to control for initial plating
differences.
Animal experiments
The animal protocols were approved by the Institutional
Animal Care and Use Committee at the University of
Virginia and were in accordance with the US Public
Health Service Policy on Humane Care and Use of
Laboratory Animals and the US Animal Welfare Act.
Four-week-old athymic nude mice were purchased from
Harlan Laboratories (Indianapolis, IN, USA) and housed
under barrier conditions. The mice were killed whenever
established criteria for pain and discomfort—in particular,
cachexia or spinal paralysis, or tumor burden—were
reached.
Bone metastasis model
Tumor cells were trypsinized, washed twice and resus-
pended at 106 cells/ml in PBS. The mice were anesthetized
using ketamine and xylazine. Intracardiac inoculations of
105 cells were performed by percutaneous injection into
the left cardiac ventricle of 5-week-old female nude mice
(n = 12 per cell line) using a 26-gauge needle [25]. The
MDA-MB-231 breast cancer cells used in vivo cause re-
producible metastasis to the appendicular skeleton in
100% of inoculated mice, visible on X-rays by 3 weeks.
This is the most commonly used model of skeletal metas-
tasis, and it mimics the final stages of colonization of boneand growth of lesions to detectable size. As such, it has
been used extensively for identification of preclinical tar-
gets and drug candidates. The breast cancer cells do not
metastasize from the primary site and do not cause lung
metastases, although other sublines of MDA-MB-231 do
so [26]. All mice were inspected post mortem for metasta-
ses outside of bone. None were found.
Radiography and analysis of osteolytic lesions
The mice were X-rayed weekly starting at 2 weeks after
tumor cell inoculation with an MX-20 digital radiography
system and digital camera (Faxitron Bioptics, Tucson, AZ,
USA). Each mouse was X-rayed at 1× magnification in prone
and lateral positions. Magnified images (4× magnification) of
suspected lesions were obtained. Osteolytic lesion areas were
analyzed on digital images using MetaMorph software
(Molecular Devices, Sunnyvale, CA, USA).
Bone histology and computerized quantitative
histomorphometry
Hind limbs were fixed for 48 hours in 10% neutral buffered
formalin, decalcified in 10% ethylenediaminetetraacetic
acid for 2 weeks, processed and embedded in paraffin
wax. An automated microtome (HM 355S; MICROM
International, Walldorf, Germany) was used to cut 3.5-μm-
thick, longitudinal, midsagittal sections of the embedded
tissue. Sections were stained with hematoxylin and eosin
(H&E) and TRAP (for the identification of osteoclasts) for
histomorphometric analysis. Images were captured with a
Leica DM LB compound microscope (Leica Microsystems,
Buffalo Grove, IL, USA) and a QImaging MicroPublisher
cooled charge-coupled device color digital camera
(QImaging, Surrey, BC, Canada). MetaMorph software
was used to analyze total tumor burden and osteoclast
number in multiple sections from the femora and tibiae of
the hind limbs. Tumor burden was defined as the area
of bone occupied by the tumor at 50× magnification
of H&E-stained sections [27]. Osteoclast number per milli-
meter of bone surface at the interface with tumor was
measured from TRAP-stained tibiae at 200× magnification.
Mammary fat pad model
Tumor cells were inoculated into the pectoral MFPs of
5-week-old female nude mice using a 27-gauge needle
(two MFPs/mouse; ten mice/cell line). A total of 106
cells in 100 μl of PBS were injected per MFP. Tumors
were measured by caliper three times per week. Tumor
burden was calculated by using the following formula:
tumor volume = 4/3π × L/2 × (w/2)2, where L = midaxis
length and w = midaxis width.
CD31 immunohistochemistry
Immunohistochemical analyses were performed on
formalin-fixed, paraffin-embedded MFP sections. Rat
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purchased from BD Pharmingen (San Jose, CA, USA).
Proteinase K was used for antigen retrieval. Ten percent
normal rabbit serum in PBS was used as the blocking
agent. The secondary antibody, biotinylated rabbit anti-rat
immunoglobulin G, was obtained from Chemicon Inter-
national (Temecula, CA, USA). Antibody binding was
visualized using VECTASTAIN Elite ABC kits (Vector
Laboratories, Burlingame, CA, USA) and diaminobenzi-
dine kits (DakoCytomation, Glostrup, Denmark). Samples
were counterstained with hematoxylin. CD31-stained ves-
sels were counted as described elsewhere [28] in two 200×
magnified images for four tumors for each cell line.
Osteoclast formation in vitro
Bone marrow was flushed from 5-week-old C57BL/6 mice
and plated at 1.9 × 106 cells/well in a 48-well plate, along
with 5 × 104 primary osteoblasts derived from neonatal
mouse calvariae by multiple digestions with dispase and
collagenase. Bone marrow and/or osteoblast co-cultures
were grown in α-minimal essential medium supplemented
with 10% FBS and 1% penicillin/streptomycin. Cells
were treated for 6 days with medium alone, 10−7 M
AM (Bachem, Bubendorf, Switzerland), 10−7 M PAMP
(Bachem) or 10−8 M 1,25-dihydroxyvitamin D3 (Enzo
Life Sciences, Farmingdale, NY, USA). Cells were fixed
with citrate/acetone/formaldehyde solution and stained
for TRAP using a leukocyte acid phosphatase kit (Sigma
Diagnostics, St Louis, MO, USA). Cells that stained posi-
tive for TRAP with three or more nuclei were counted
and compared [29].
Ex vivo bone organ cultures
Neonatal mouse calvarial bone explants were trimmed
and cultured for 7 days in serum-free BGJb medium
(Life Technologies, Carlsbad, CA, USA), which was chan-
ged every 48 hours, in the presence or absence of 100 nM
AM. New bone formation was determined by quantitative
histomorphometry of decalcified sections [30]. Primary
osteoblasts were isolated from the same neonatal calvarial
source [31].
Ex vivo growth of tumor with bone
Segments of neonatal mouse bone were prepared by using
a modification of the method described by Mohammad
et al. [30]. Calvariae from killed 11-day-old C57BL/6
mouse pups were cut into 3-mm disks with a biopsy
punch and placed into wells of uncoated 24-well plates.
Breast cancer cells (5 × 103) were added to 0.5 ml of BGJb
medium supplemented with 20% fetal calf serum, 500 nM
human insulin and 100 μM ascorbic acid. Plates were
incubated at 37°C in 5% CO2. The medium was chan-
ged every 2 to 3 days. At day 6, bones were washed in
PBS, placed in 1.0 ml of QIAzol lysis reagent (QIAGEN,Valencia, CA, USA) and homogenized for 1 minute with
zirconium beads in a BeadBug microtube homogenizer
(Benchmark Scientific, South Plainfield, NJ, USA) at 280
strokes/min according to the manufacturer’s instructions.
Aqueous phase RNA was isolated using an RNeasy Mini
Kit (QIAGEN). First-strand cDNA for PCR was made with
an iScript cDNA synthesis kit (Bio-Rad Laboratories,
Hercules, CA, USA). Breast cancer cells were transduced
with lentiviral particles from GenTarget (San Diego, CA,
USA), according to the manufacturer’s instructions, with a
vector encoding secreted Cypridina luciferase driven by a
CMV promoter, plus a red fluorescent protein (RFP)-blas-
ticidin fusion protein cassette for selection. RFP-positive
MDA-MB-231 cells were isolated by fluorescence-activated
cell sorting. Secretion of luciferase was used as an indicator
of tumor burden [32] by assay of conditioned media
with a BioLux Cypridina luciferase assay kit obtained
from New England BioLabs (Ipswich, MA, USA) and a
Turner BioSystems TD 20/20 luminometer (Promega).
The results were expressed as relative luminescence
units.
PCR experiments
Total RNA was isolated using QIAGEN RNeasy Mini
Kits including treatment with DNase. RNA was con-
verted to cDNA using Omniscript RT Kits from QIA-
GEN with 16-mer oligo(dT) primers and then analyzed
by PCR with an Eppendorf Mastercycler (Eppendorf,
Hamburg, Germany) or by quantitative PCR using the
QuantiTect SYBR Green PCR Kit (QIAGEN) and an
iCycler Single-Color Real-Time Detection System (Bio-Rad
Laboratories). Human AM mRNA was detected using
these primers: forward, 5′-GGA-AGA-GGG-AAC-TGC-
GGA-TGT-3′; reverse, 5′-GGC-ATC-CGG-ACT-GCT-
GTC-T-3′. To normalize the data, human ribosomal
protein L32 (RPL32) mRNA was amplified with the
following primers: forward, 5′-CAG-GGT-TCG-TAG-
AAG-ATT-CAA-GGG-3′; reverse, 5′-CTT-GGA-GGA-
AAC-ATT-GTG-AGC-GAT-C-3′. Relative mRNA ex-
pression was calculated using the 2−ΔΔCT method [33].
Species-specific PCR primers were designed with the
online Primer3 tool [34] and tested for species specificity
with the National Center for Biotechnology Information
(NCBI) primer design tool [35] by Blast searching against
the targeted sequence and versus both Mus musculus and
Homo sapiens sequence databases to eliminate cross-
species and erroneous amplifications and allowing ampli-
fication of transcript variants. The templates used for
primer design were GenBank RefSeq files for the desig-
nated genes. The NCBI primer design tools proved un-
satisfactory for the initial design of primers suitable for
species-specific amplification. Primers were then sep-
arately tested using real-time PCR with cDNAs from
mouse calvariae and human tumor cells. Primer sets
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proper species and gave single melt curve peaks, a cycle
efficiency >95%, threshold cycle values <33 and only one
band of DNA of the appropriate size on gel electrophor-
esis. All PCR data were normalized to the ribosomal large
subunit protein 32 housekeeping control, RPL32, specific
to mice or humans [36]. A lower case m or h in front of
gene symbols indicates mouse or human specificity.
Additional species-specific primer sequences can be
found in the Additional file 1.
Statistical analyses
Data were compiled in Microsoft Excel files (Microsoft,
Redmond, WA, USA) and analyzed with GraphPad Prism
software (GraphPad Software, La Jolla, CA, USA). Two-
way analysis of variance (ANOVA) with the Bonferroni
posttest was used to determine differences between
osteolytic lesion area, MFP tumor volume and prolifera-
tion in vitro. One-way ANOVA with Tukey’s multiple-
comparisons posttest was used for histomorphometric
analysis to determine differences in tumor area and
osteoclast number per millimeter of tumor–bone inter-
face, osteoclast number in the bone marrow/osteoblast
co-cultures, number of CD31+ vessels, bone formation
in calvarial cultures and changes in gene expression in
tumor/bone co-cultures. Logrank analysis was used to
assess differences between survival curves. The results
are shown with mean ± standard deviation and statistical
significance levels of *P < 0.05, **P < 0.01, ***P < 0.001.
Significance is in comparison to controls in all figures,
except where stated otherwise.
Results and discussion
Breast cancer cell lines that metastasize to bone express
adrenomedullin
Human breast cancer cell lines previously described to
metastasize to bone in mice following intracardiac in-
oculation [27] were surveyed for AM mRNA. The ma-
jority of breast cancer lines were positive, including the
osteolytic lines MDA-MB-231 and BT549; the osteo-
blastic lines ZR75, MCF-7 and T47D; and MDA-MB-
436 and MDA-MB-361, which do not metastasize to
bone. Only BT438 lacked detectable AM mRNA. Other
human tumors metastatic to bone expressed AM, in-
cluding PC-3 prostate cancer cells, A549 lung cancer
cells and MDA-MB-435 melanoma cells. Normal tissues
expressed AM, including breast, kidney and prostate
(Figure 1A). The data do not suggest that AM expres-
sion contributes to specific tropism to bone character-
istics of certain tumors.
Because of its potent stimulatory activity toward osteo-
blasts, AM could contribute to the growth of tumors
that have already metastasized to skeletal sites. First, we
tested the effects of increased AM expression on theprogression of osteolytic bone metastases caused by
MDA-MB-231 cells, which were chosen because low-
expressing lines such as MCF7 and T47D show sub-
stantially altered phenotype and growth in vitro when
transfected with AM [37] and cause more indolent
bone metastases than MDA-MB-231 cells [25], which
are the standard and most widely used model of skeletal
metastases [38]. Tumor growth was followed in the MFP
in a separate experiment to control for in vivo effects of
AM not specific to bone.
Generation of MDA-MB-231 clones with fivefold increased
expression of adrenomedullin
Cells were transfected with either the pIRESneo3-hAM
or pIRESneo3-emGFP plasmid. emGFP expression was
used for the control to minimize differences in growth
rate of transfectants often encountered after selection
for antibiotic resistance. Single-cell clones were grown
for 60 days without antibiotics to test for stable overex-
pression. We selected two clones with stable fivefold
overexpression of human AM mRNA (Figure 1B) and
five clones with stable GFP expression detected by fluor-
escence microscopy. The proadrenomedullin precursor
encodes PAMP in addition to AM. The PAMP concen-
tration in media conditioned by the tumor cells was less
than the limit of detection of the assay, 0.08 ng/ml, per-
haps due to proteolytic degradation of the peptide.
Tumor-secreted AM peptide concentrations ranged from
0.9 to 2.5 ng per 10 million cells per 24 hours by enzyme
immunoassay in media conditioned by the cell lines, but
did not correlate with mRNA levels. MDA-MB-231 cells
express complement factor H (data not shown), which
binds AM with nanomolar affinity, interfering with detec-
tion of the peptide [3].
Two AM-overexpressing clones (A39 and A51) and
two GFP control clones (G8 and G26) were used for fur-
ther experimentation (Figure 1B). The members of each
pair were compared to ensure that responses were not
due to clonal variation. The four clones showed no sig-
nificant growth differences in vitro as measured by MTT
assay (Figure 1C). Overexpression of AM in T47D breast
cancer cell cells did not alter proliferation in vitro, unless
the cells were grown serum-free [37]. AM overex-
pression in T47D cells increased the percentage of
cells in sub-G0/G1-phase and decreased the percent-
age in S-phase. AM overexpression in MDA-MB-231
cells did not alter progression through the cell cycle
as determined by flow cytometric analysis of propidium
iodide–stained cells (data not shown) or expression (ana-
lyzed by PCR) of a panel of tumor-secreted factors import-
ant in bone metastasis [20,39]: interleukin 11 (IL-11),
PTHrP, IL-8, cysteine-rich protein 61, connective tissue
growth factor and vascular endothelial growth factor (data
not shown).
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Figure 1 Adrenomedullin expression by breast cancer cell lines and effects of adrenomedullin on tumor and bone cells. (A)
Adrenomedullin (AM) RNA in human breast cancer cell lines that metastasize to bone. PCR detection of human AM mRNA in from left to right:
normal tissues (kidney, prostate and breast), breast cancer cell lines (MCF-7, BT549, MDA-231, MCF-7, MDA-MB-436, ZR-75-1, T47D, MD-MB-361
and BT438) and three additional cancer cell lines that cause osteolytic bone metastases: MDA-MB-435S melanoma cells, PC-3 prostate cancer cells
and A549 lung adenocarcinoma cells. cDNA (200 ng) was amplified for 30 cycles. The PCR product is 600 bp. It is unclear if kidney expresses only
low amounts of AM mRNA or if the RNA was degraded. (B) Stable overexpression of human AM mRNA in MDA-MB-231 cells. Clones were tested
for stable human AM mRNA expression using real-time PCR after 60 days of culture in the absence of antibiotic selection. G8-G31 are MDA-MB-231
control clones, and A15-A51 are MDA-MB-231 clones overexpressing AM. (C) Proliferation in vitro of breast cancer cells. Proliferation of two
AM-overexpressing clones (A39, gray triangle; A51, black triangle) and two control clones (G8, gray square; G26, black square) were compared
using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; tetrazolium blue dye) assay. Proliferation was compared after 1, 3 and 5 days
of growth. OD, Optical density.
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metastases
Nude mice inoculated with MDA-MB-231 cells by the
intracardiac route reproducibly develop metastases to
the appendicular skeleton, characterized by radiolucent
regions visible on X-rays, indicating destruction of bone
by tumor-associated osteoclasts. The cells rarely colonize
to other sites, and the animals develop paraplegia and
cachexia requiring that they be killed 4 weeks after inocu-
lation [25,38]. Two AM-overexpressing, two GFP control
clones and parental cells were injected into the left cardiac
ventricle of female nude mice. AM-overexpressing clones
(Figure 2A, right panel) caused a significantly increased
total osteolytic lesion area (indicated by arrows pointing
to radiolucent regions) in bone compared to either GFP
control cells (Figure 2A, left panel) or parental cells as
measured by X-ray (19.3 mm2 vs. 6.1 mm2 at 3 weeks,
32.5 mm2 vs. 16.9 mm2 at 4 weeks; P < 0.001 for compari-
son of AM-overexpressing clones versus GFP control
clones grouped together) (Figure 2B). The GFP control
clones produced total osteolytic lesion areas similar to
each other and the parental cell line (P = not significant).The AM-overexpressing clones produced total bone
osteolytic lesion areas similar to each other (P = not
significant). We inspected the histological sections for
evidence of osteoblastic lesions because AM stimulates
new bone formation, but we found no regions of clear
osteoblastic reaction to tumor. Changes in osteoblasts
are seldom seen in models of skeletal metastases, and
methods for their quantification are lacking. We found
no gross evidence of metastases to soft tissue sites in
any of the mice. AM overexpression significantly de-
creased the overall survival of the mice from 30 to 25 days
(Figure 2C).
Tumor-bearing limbs were examined histologically.
Figure 3A shows representative lesions, with a control tumor
(T) shown in the left panel, a large AM-overexpressing
tumor depicted in the center panel adjacent to bone (white
arrow) and a region magnified in the right panel, showing a
multinucleated osteoclast (dark arrow) at the tumor–bone
interface. In the left and center panels, tumor has filled the
marrow cavity below the growth plate, destroying trabecular
bone and eroding endocortical bone. These features are typ-
ically seen in this model [25,38]. Total tumor area in the legs,
***
**
A
B C
Figure 2 Adrenomedullin overexpression increases osteolytic bone destruction and decreases survival in mice. Two control (G8 and G26)
and two adrenomedullin (AM)-overexpressing (A39 and A51) MDA-MB-231 clones were injected into the left cardiac ventricle of female athymic nude
mice (n = 12/cell line). (A) Representative radiographs of the bone destruction due to control (left panel) and AM-overexpressing clones (right panel) at 4
weeks after tumor cell inoculation. Original magnification, ×4. Arrows point to osteolytic lesions. (B) Quantitative radiographic lesion analysis of
MDA-MB-231 control and AM+ clones over time (G8, gray square; G26, black square; A39, gray triangle; A51, black triangle). *P < 0.05, **P < 0.01.
(C) Mouse survival. The two control clones (G8 and G26, black squares) and the two AM+ clones (A39 and A51, black triangles) were grouped together
in the analysis.
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doubled (P < 0.05) when the tumor overexpressed AM
(Figure 3B). This determination was necessary because the
osteolytic lesion area shown on the X-ray (Figure 2B) is
not a direct measure of tumor burden. The number of
bone-resorbing cells along the tumor–bone interface was
also determined histomorphometrically. Multinucleated
osteoclasts were identified by staining for the marker TRAP.
The AM-overexpressing group had a number of osteoclasts
along the tumor–bone interface similar to those of the GFP
control groups (Figure 3C). The AM-overexpressing group
was analyzed sooner after tumor inoculation than the GFP
control group because of differences in survival. Thus, AM
overexpression reduced the time by 5 days for tumors to
stimulate formation of equivalent numbers of osteoclasts
compared to GFP control tumors. Because this was a sur-
vival experiment, it was not possible to analyze osteoclast
numbers earlier during the process of bone destruction,
when they could be increased by AM versus controls.
There are no reports that AM directly stimulates oste-
oclasts. We tested if AM or PAMP affected osteoclasto-
genesis in mouse bone marrow/osteoblast co-cultures.
AM or PAMP peptide (10−7 M) did not increase TRAP-
positive, osteoclast-like multinucleated cells compared to
the untreated control (Figure 4A), whereas the positive
control, 100 nM 1,25-dihydroxyvitamin D3, significantlyincreased TRAP-positive multinucleated cells. These re-
sults have been confirmed by others [19]. AM could in-
crease early osteoblasts during the development of bone
lesions [17,18] because cells in the osteoblastic lineage
control osteoclasts, which are responsible for increased
bone destruction. This regulation of osteolysis is via
osteoblastic expression of RANKL, the central regula-
tor of osteoclast formation, survival and activity [40].
Adrenomedullin overexpression increased MDA-MB-231
growth in mammary fat pads
AM overexpression caused larger MFP tumors com-
pared to the GFP control clones (462 mm3 vs. 160 mm3
at day 21; P < 0.001) (Figure 4B). GFP control clones
produced tumor volumes similar to each other, and
AM-overexpressing clones also produced tumor volumes
similar to each other (P = not significant). Martínez et al.
also found that AM overexpression increased subcutane-
ous tumor growth of T47D breast cancer cells [37],
although overexpression had the opposite effect in a
prostate cancer model [41].
AM is proangiogenic, and many angiogenic factors,
such as vascular endothelial growth factor and connective
tissue growth factor, stimulate breast cancer bone metasta-
ses [20]. We compared the number of vessels in vascular-
ized regions of MFP tumors using immunohistochemical
AB C
Figure 3 Histomorphometric analysis of bone metastases. (A) Representative histological images of mouse femoral sections. Left image
represents the control group, and middle image represents the adrenomedullin (AM)-overexpressing group (hematoxylin and eosin stain; original
magnification, ×31.25). Right image is a magnified region of an area in the AM-overexpressing bone metastasis that has osteolytic bone destruction
tartrate-resistant acid phosphatase (TRAP) stain; original magnification, ×400). White arrow in middle image points to the magnified region shown in the
right image. Tumor is labeled “T.” Black arrow points to a TRAP-positive (TRAP+; red) osteoclast along the tumor–bone interface. (B) Tumor burden in bone.
Quantitative histomorphometric analysis of tumor area in the legs (tibia and femur). The two control (G8 and G26) and the two AM-overexpressing clones
(A39 and A51) are grouped together in the graph. *P < 0.05. (C) Osteoclast numbers. TRAP+ osteoclasts along the bone–tumor interface were counted.
There was no significant difference between the groups.
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The numbers of CD31-positive vessels were similar in the
AM-overexpressing MFP tumors compared to controls
(P = not significant) (Figure 4D). This was confirmed
by staining for a second endothelial marker, von Will-
ebrand factor (data not shown). MDA-MB-231 cells
cause aggressive tumors in xenograft models and already
express high levels of angiogenic factors; thus, increasing
the expression of AM may have no additional effect on
neoangiogenesis induced by this cell line.
Our data suggest that increased growth of AM-
overexpressing MDA-MB-231 tumors is not due only
to direct effects of AM on bone cells. AM is one of
three vasoactive factors that increase the growth of
breast cancer bone metastases. The vasorelaxant parathy-
roid hormone-related protein, PTHrP, increases osteolytic
bone metastases, whereas the vasoconstrictor endothelin
1 (ET-1) stimulates osteoblastic metastases in breast
cancer models [25,27]. Vasoactive factors can alter tumor
perfusion, and vasodilatation by AM increases tumor per-
fusion [42]. In the cases of PTHrP and ET-1, blockade of
these factors decreases bone metastases without effects onMFP tumors [25,27], indicating that factor actions on os-
teoblasts outweigh opposing effects on tumor perfusion.
A major pathway by which AM may increase breast can-
cer growth in both MFP and bone may be via increased
perfusion and oxygenation of the tumor. Future experi-
ments are required to test this mechanism, but, at this
point, the mechanisms by which AM overexpression in-
crease growth in the MFP are unclear.
AM plays an important role in the growth and metastasis
of many tumor types, where its transcription is increased
by the hypoxia-response pathway, and it also stimulates
bone cells. Our results establish that AM can accelerate
bone metastasis in a standard breast cancer model. PTHrP
expression by MDA-BM-231 cells dramatically increases
osteolytic bone lesions [43] through actions on osteoblasts
[44], cells which are stimulated by AM. The literature sug-
gests that AM often exerts a general tumor-stimulatory ef-
fect. Our data show that it can increase bone metastases as
well. AM is thus a potential drug target because it can
stimulate cancer growth by autocrine effects on tumor plus
paracrine effects on the microenvironment—a dual action
that has been reported in pancreatic cancer [45].
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Figure 4 Adrenomedullin did not affect tumor vascularization or osteoclastogenesis but increased tumor growth in the mammary fat pad.
(A) and (B) show tumor vascularization. (A) Representative mammary fat pad tumor section stained for CD31. Arrows point to vessels with brown
immunostaining (original magnification, ×640). (B) Quantification of CD31+ vessels in tumor. Fields containing stained vessels were counted per
×200 magnification field (two fields per tumor, four tumors per cell line). There was no significant difference between the groups. (C) Mammary
fat pad growth. Two control (G8 and G26) and two adrenomedullin (AM)-overexpressing (A39 and A51) MDA-MB-231 clones were injected into
the mammary fat pad of female athymic nude mice (n = 10 mice/cell line; n = 2 mammary fat pads/mouse). Data for two control clones (black
squares) and the two AM-overexpressing clones (black triangles) were grouped together for the analysis. *P < 0.05, **P < 0.01, ***P < 0.001. (D)
Osteoclast formation in vitro was unchanged by AM or 20–amino acid proadrenomedullin peptide (PAMP). D3 indicates the positive control,
1,25-dihydroxyvitamin D3. TRAP+, Tartrate-resistant acid phosphatase–positive. MNC, Multinucleated cells.
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on bone cells
AM inhibition could be a useful treatment for both pri-
mary tumors and bone metastases. Peptide antagonists
[12,14] successfully decrease primary tumor growth in
mice, as do neutralizing antibodies [11,13]. Such inhibi-
tors could be used to reduce both primary tumor growth
and osteolysis in breast cancer patients. Greater selectiv-
ity of inhibition may be obtained with small-molecule
drugs that bind the circulating AM peptide and lock it
into antagonist conformations [24,46], which then sup-
press receptor-mediated responses. We tested three of
the antagonists from an NCI library of compounds [47],
studied by Martínez et al., for effects on bone in ex vivo
calvarial organ cultures (Figure 5). The general methods
of this assay are detailed elsewhere [30], and the response
of neonatal bone to AM is shown in Additional file 1:
Figure S1. The two effective ones, 16311 and 37133
(Figure 5C), are both simple aromatic carboxylic acids whose
negative charge in solution may make them membrane-
impermeant. The former has a dissociation constant for
binding to AM of 8 nM without altered ligand–receptor
association [24]. A third aromatic carboxylic acid,28086 (Figure 5C), was ineffective in the assay (data
not shown). We also tested 16311 and 37133 for effects
on growth of primary osteoblasts isolated from neonatal
mouse calvariae over a 48-hour period by MTT assay.
There was no growth inhibition at concentrations from
10−8 to 10−3 M (Additional file 1: Figure S2). Their
ability to block the bone-selective actions of AM and
lack of cellular toxicity lends itself to further development
of these small molecules for animal testing against breast
cancer xenografts.
Adrenomedullin antagonist 16311 decreases osteolytic
factors TRAP and RANKL and growth of MDA-MB-231 cells
in bone
The AM antagonist compounds [24] are untested against
tumor growth in vivo because their pharmacokinetics and
pharmacology for absorption, distribution, metabolism
and excretion are unknown. We therefore studied one
of them in a new ex vivo model of tumor–bone inter-
action [48] in which tumor cells are co-cultured for 1
week with neonatal calvarial bones. We have modified
this procedure to resemble more closely the standard
procedure for testing the effects of isolated factors on
AC
B
Figure 5 Small-molecule antagonists block adrenomedullin-induced bone formation. Two small molecules blocked adrenomedullin (AM)-induced
bone formation. Neonatal mouse calvarial bones were cultured in triplicate for 7 days and treated with 10 nM AM ± 1 μM inhibitor NSC 16311 (A) or NSC
37133 (B). Sections were assessed for new bone formation, expressed as area in histological sections, indicated on the vertical axis, by
quantitative histomorphometry. ***P < 0.001. An example of the assay is provided in Additional file 1: Figure S1. (C) Chemical structures of
the NSC compounds are shown [47].
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million. Representative images of the assay are pro-
vided in Additional file 1: Figure S3. The breast cancer cells
were engineered stably to express a secreted Cypridina
luciferase for noninvasive monitoring of tumor burden
by assaying luciferase activity in the medium [32]. At
the end of the incubation period, RNA was isolated
from the co-cultures and assayed by species-specific
real-time PCR [36] for changes in (human) tumor and
(mouse) bone gene expression, an approach which yields
more useful quantitative data than histology (Additional
file 1: Figure S3).
When MDA-MB-231 breast cancer cells were added
to calvarial cultures, there was a substantial increase in
tumor burden over the course of 6 days, as indicated by
the secreted luciferase marker. Tumor activity was mod-
estly but significantly further increased by supplementa-
tion with 10 nM AM peptide. In contrast, the addition
of the 16311 antagonist to tumor/bone co-cultures dra-
matically decreased tumor burden in the absence of
added AM (Figure 6A). Antagonist alone had no appar-
ent effect on bone (Figure 5A). The species-specific PCR
analysis of these cultures confirmed that AM (in thepresence or absence of tumor) increased the marker of
osteoblast activity, type 1 collagen, consistent with the
stimulation of bone formation seen with AM [16]
(Additional file 1: Figure S1). MDA-MB-231 cells alone
(with or without the 16311 antagonist) caused modest
suppression of collagen mRNA (Figure 6B). To interro-
gate the mechanism underlying the tumor–bone interac-
tions altered by AM, we looked at markers of osteoclast
activity and osteoclast regulation because increased osteo-
lytic bone destruction is a hallmark of breast cancer bone
metastases and a central contributor to the vicious cycle
[20]. Osteoclast formation is controlled by RANKL, which
regulates osteoclast formation, survival and activity. Its
action is opposed by a soluble binding protein, osteo-
protegerin (Opg). Both proteins are made by cells of
the osteoblastic lineage. Active osteoclasts destroy bone
through the controlled secretion of acid and enzymes, in
particular TRAP and cathepsin K. We found that adding
MDA-MB-231 cells to bone increased TRAP expression.
AM alone had no effect, whereas the addition of AM to
cultures containing breast cancer cells further increased
bone expression of TRAP mRNA. Induction of TRAP by
breast cancer cells was completely blocked by the addition
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Figure 6 Effects of adrenomedullin antagonist on MDA-MB-231 cells in bone. All indicated P-values are versus control. (A) Growth. Addition
of 10 nM adrenomedullin (AM) peptide (black triangles) increased tumor growth as measured by secreted luciferase marker in conditioned
media. Significant vs control (*P < 0.05) at 3 and 6 days. Addition of 1 μM AM antagonist 16311 (black squares) dramatically decreased tumor
growth vs control after 3 days (**P < 0.001) and 6 days (***P < 0.0001). RLU, Relative light unit. (B) Osteoblast activity. Bone biosynthetic collagen
marker, type I collagen (mCol1A1). Exogenous AM increased mouse collagen mRNA in the presence and absence of tumor, whereas tumor alone
(with or without 16311 antagonist) modestly suppressed this marker of osteoblast function. (C) Osteoclast activity. The mouse bone marker
tartrate-resistant acid phosphatase (TRAP), encoded by mACP5, was increased by tumor cells, further increased by tumor plus exogenous AM and
blocked by the 16311 AM antagonist. AM alone had no effect on TRAP mRNA. (D) Receptor activator of nuclear factor κB ligand (RANKL). Samples
were analyzed for both mouse and human RANKL expression because both tumor cells and bone cells can express this factor, which regulates
osteoclast formation, survival and activity. Control is bone without tumor or treatment, where the expression of mouse RANKL = 1. Levels of
human RANKL (gray bars) are adjusted to the equivalent threshold cycle values so that the absolute amounts of mouse and human RANKL
are expressed on the same scale. In (D) only, # indicates significance relative to each of the other relevant columns within the mouse or human
groups (#P < 0.0001) by one-way analysis of variance. No other pairwise comparisons were significantly different, and mouse and human datasets were
not compared.
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indicated in Figure 6C are all relative to control (bone
without tumor). In addition, when columns 2 and 4 were
compared (bone with tumor with or without exogenous
AM) by one-way ANOVA, the addition of 1 nM AM sig-
nificantly augmented TRAP mRNA (P < 0.01). Responses
similar to those seen with TRAP were also observed forcathepsin K (Additional file 1: Figure S4A). We had
previously observed a dramatic increase in expression
of RANKL mRNA by MDA-MB-231 cells grown in
bone, and such expression has been reported by others
[49]. Therefore, we assayed for tumor and bone expres-
sion of RANKL, both of which are readily distinguished
by PCR with species-specific primers. Figure 6D shows
Siclari et al. Breast Cancer Research  (2014) 16:458 Page 12 of 14that AM alone does not alter RANKL expression, consist-
ent with its lack of effect on osteoclasts. MDA-MB-231
cells alone suppress mouse RANKL mRNA, whereas the
presence of bone induces tumor expression of human
RANKL. Addition of 10 nM AM to the system reverses
the expression pattern, so that mouse bone RANKL is
abundant and human tumor RANKL is low. Both re-
sponses in RANKL were statistically significant. The
addition of 16311 antagonist blocked expression of
RANKL from both sources. The RANKL-neutralizing
protein Opg was very low in all groups (Additional file
1: Figure S4B). An early discovery of a vicious cycle in
breast cancer bone metastases was with the osteolytic
factor PTHrP, which is made by MDA-MB-231 cells
and acts indirectly by increasing stromal RANKL expres-
sion [44]. We found that tumor expression of PTHrP
in the presence of bone was unchanged by treatment
with AM or the 16311 antagonist (Additional file 1:
Figure S4C). Thus, the changes in RANKL and in osteo-
clast markers that we observed were not responses to
changes in PTHrP. Overall, the results show that AM in-
creases tumor-induced osteolysis in bone by altering local
production of RANKL. This change, as well as tumor
growth, could be blocked with the 16311 antagonist.
Our data (Figure 4D), as well as results published else-
where by others [19], show that simple addition of AM
peptide to bone cultures does not increase osteoclasts.
How, then, does AM in the tumor microenvironment
accelerate osteolytic bone metastases? AM stimulates os-
teoblasts and bone formation, and cells in the osteoblast
lineage regulate osteoclasts via the RANKL pathway.
RANKL is expressed by bone stromal cells and by osteo-
cytes, cells early and late in the osteoblast lineage, where
a variety of tumor-secreted products increase RANKL
expression [50]. AM could increase the number of
RANKL-expressing cells or potentiate their production
of RANKL in response to osteolytic factors such as IL-6
or PTHrP. The data in Figure 6D show that the addition
of tumor cells resulted in a fourfold increase in bone
RANKL mRNA, a response that is abrogated by adding
AM antagonist. These results are consistent with the
changes seen in the osteoclast marker TRAP mRNA in
Figure 6C. AM retained its ability in these co-cultures to
stimulate the osteoblast marker type I collagen (Figure 6B),
regardless of the presence of tumor cells. The dramatic
switch in the source of RANKL expression (from tumor
to bone) upon addition of a high dose of AM peptide,
shown in Figure 6D, was unexpected and remains without
a compelling explanation. Osteocytes are a major source
of RANKL [40], but the effects of AM on these cells are
not known. Tumor cells can also be a source of RANKL
in osteolytic lesions [51]. RANKL decreases AM receptor
signaling via alterations in cAMP [19]. So, interactions be-
tween signaling pathways involving AM could contributeto the switch in cellular source of RANKL. In recent stud-
ies with the MDA-MB-231 model of bone metastases,
researchers found that crosstalk between tumor and
osteoblastic cells increased metastatic growth via a
subsidiary vicious cycle in which IL-6 and RANKL in-
creased one another in the metastatic microenvironment
[52]. AM can increase IL-6 expression in mesenchymal
cells, but this has not been shown with osteoblasts or
cancer cells. The role of AM in regulation of RANKL
expression in bone metastases is a subject of ongoing
investigation.
Conclusions
Tumor-expressed AM contributes to the growth of breast
cancer cells as osteolytic metastases in bone. The general
phenotype of the bone lesions was unaltered by increased
AM, but the rate of their growth was increased and was
accompanied by shorter survival. AM overexpression also
increased growth of tumor in the MFP, but not in vitro, in
the absence of increased angiogenesis, by unknown mech-
anisms. Our results with overexpression of the AM
peptide in a standard animal model, combined with ex-
periments in ex vivo co-cultures of cancer cells with
bone, provide the first proof of principle that AM may
be a useful target for the treatment of breast cancer
bone metastasis. A small-molecule inhibitor blocked
bone responses to AM ex vivo without general cellular
toxicity and decreased osteoclast markers and tumor
growth in bone. Our data support preclinical develop-
ment of AM antagonists for in vivo testing and future
treatment of osteolytic metastases due to breast cancer.
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